蒋洋

Yang Jiang, Ph.D.

Postdoctoral Fellow of Shanghai Institute of Nutrition and Health

CAS Key Laboratory of Nutrition, Metabolism and Food Safety

Chinese Academy of Sciences

Phone: 021-5492-0924

Education Background & Academic Experience:

Dr. Jiangyang received his Bachelor's degree (2018) and Ph.D. (2024) from the College of Biotechnology at Tianjin University of Science and Technology. He subsequently joined the Li Lab at the Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, in July 2020 to pursue his doctoral research and began his postdoctoral training in the same lab in June 2024.

Research Interests:

His research focuses on the molecular mechanisms underlying the regulation of glucose/lipid metabolism and the pathogenesis of fatty liver disease. Recently, he elucidated how FGF21 ameliorates MASH via PPP6C and investigated the role of the small compound ethyl lactate in regulating ethanol-induced hepatic lipogenesis in ALD. He is also exploring the role and mechanisms of the central nervous system in the progression of fatty liver disease.

Grants and Funding:

His research were funded by the Youth Project of National Natural Science Foundation of China (国家自然科学基金委青年项目), the Youth Projects of Natural Science Foundation of Shanghai (上海市“自然科学基金”青年项目) and the Project of China Postdoctoral Science Foundation (中国博士后科学基金会面上项目).

Personal interests and hobbies:

His MBTI personality type is ISTJ (Introversion, Sensing, Thinking, Judging). He is passionate about triathlon (swimming, cycling, and running), marathon running and strength training.

Peer-reviewed Publications:

1. Liu Z#, Wei S#, Jiang Y#, Su W, Ma F, Cai G, Liu Y, Sun X, Lu L, Fu W, Xu Y, Huang R, Li J, Lin X, Cui A, Zang M, Xu A, Li Y*. Protein phosphatase 6 regulates metabolic dysfunction-associated steatohepatitis via the mTORC1 pathway. Journal of Hepatology. 2025, DOI: 10.1016/j.jhep.2025.02.003

2. Jiang Y#, Wei S#, Shen S, Liu Y, Su W, Ding D, Zheng Z, Yu H, Zhang T, Yang Q, Zhao J, Shen Y, Fang X, Lin L, Xiao D, Cui A*, Wan Q*, Zhang Y*, Li Y*, Zhang C*. Ethyl lactate ameliorates hepatic steatosis and acute-on-chronic liver injury in alcohol-associated liver disease by inducing fibroblast growth factor 21. Advanced Science. 2025, e2409516

3. Cui A#, Xue Y#, Su W#, Lin J, Liu Y, Cai G, Wan Q, Jiang Y, Ding D, Zheng Z, Wei S, Li W, Shen J, Wen J, Huang M, Zhao J, Zhang X, Zhao Y, Li H, Ying H, Zhang H, Bi Y, Chen Y, Xu A, Xu Y*, Li Y*. Glucose regulation of adipose tissue browning by CBP/p300 and HDAC3-mediated reversible acetylation of CREBZF. Proceedings of the National Academy of Sciences. 2024, 121(16):e2318935121

4. Ma F, Liu Y, Hu Z, Xue Y, Liu Z, Cai G, Su W, Zheng Z, Fang Z, Yan X, Ding D, Sun X, Jiang Y, Wei S, Li W, Zhao J, Zhang H, Li H, Xiao D, Zhang C, Ying H, Qin J, Gao X, Dai X, Fu W, Xu Y*, Li Y*, Cui A*. Intrahepatic osteopontin signaling by CREBZF defines a checkpoint for steatosis-to-NASH progression. Hepatology. 2023, 78(5):1492-1505